Skip to main content
. 2012 May 3;11:147. doi: 10.1186/1475-2875-11-147

Table 1.

Summary of the patient populations by treatment arm in the five clinical trials

 
  
  
  
  
  
 Day14
 Day21
 Day28
  
Study
 Year
 Treat
 m1
 m2
 m3
 ACPR
 LPF
 LCF
 ACPR
 LPF
 LCF
 NA
 ACPR
 LPF
 LCF
 NA
#                                
 
 2005
 AQ
 64
 3
 61
 58
 2
 1
 54
 0
 2
 5
 50
 2
 2
 7
 
 Feb-May
 ASAQ
 60
 3
 57
 56
 0
 1
 49
 0
 4
 4
 43
 3
 3
 8
1
  
 ASSP
 61
 3
 58
 58
 0
 0
 55
 1
 1
 1
 50
 3
 2
 3
 
 Subtotal
  
 185
 9
 176
 172
 2
 2
 158
 1
 7
 10
 143
 8
 7
 18
 
 2006 1
 AQSP
 67
 3
 64
 64
 0
 0
 61
 1
 1
 1
 55
 1
 4
 4
 
 Apr-Jul
 ASMQ
 69
 8
 61
 61
 0
 0
 61
 0
 0
 0
 60
 1
 0
 0
2
 Subtotal
  
 136
 11
 125
 125
 0
 0
 122
 1
 1
 1
 115
 2
 4
 4
 
 2006 2
 ASAQ
 62
 4
 58
 58
 0
 0
 52
 4
 1
 1
 52
 0
 0
 6
 
 Sep-Nov
 AMLM
 61
 1
 60
 60
 0
 0
 58
 2
 0
 0
 58
 0
 0
 2
3
 Subtotal
  
 123
 5
 118
 118
 0
 0
 110
 6
 1
 1
 110
 0
 0
 8
 
 2006 3
 ASCD
 86
 14
 72
 71
 1
 0
 57
 6
 8
 1
 53
 2
 1
 16
4
 Dec-Feb
 ASSP
 82
 1
 81
 81
 0
 0
 79
 0
 2
 0
 74
 2
 2
 3
 
 Subtotal
  
 168
 15
 153
 152
 1
 0
 136
 6
 10
 1
 110
 0
 0
 19
 
 2007
 ASAQ
 92
 4
 88
 87
 1
 0
 78
 6
 3
 1
 73
 5
 0
 10
5
 Apr-Jul
 DHPP
 91
 5
 86
 86
 0
 0
 86
 0
 0
 0
 84
 2
 0
 0
 
 Subtotal
  
 183
 9
 164
 173
 1
 0
 164
 6
 3
 1
 157
 7
 0
 10
 
 Subtotal
 ASAQ
 214
 11
 203
 201
 1
 1
 179
 10
 8
 6
 168
 8
 3
 24
 
  
 Others
 581
 38
 543
 539
 3
 1
 513
 10
 14
 8
 484
 13
 11
 35
  Total   795 49 746 740 4 2 690 20 22 14 652 21 14 59

m1: number of included patients, m2: number of drop-out and lost to follow-up before Day 14, m3: number of evaluated patients on Day 14. ACPR adequate clinical and parasitological response, LPF late parasitological failure, LCF late clinical failure), NA: not available outcome. AQ, amodiaquine; SP, sulphadoxine-pyrimethamine; AS, artesunate; AM, artemether; DHPP, dihydroartemisinin-piperaquine; LM, lumefantrine; CD, chlorproguanil-dapsone.